The microbiome-derived metabolite TMAO drives immune activation and boosts responses to immune checkpoint blockade in pancreatic cancer
Open accessThe DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
Abstract
The composition of the gut microbiome can control innate and adaptive immunity and has emerged as a key regulator of tumor growth, especially in the context of immune checkpoint blockade (ICB) therapy. However, the underlying mechanisms for how the microbiome affects tumor growth remain unclear. Pancreatic ductal adenocarcinoma (PDAC) tends to be refractory to therapy, including ICB. Using a nontargeted, liquid chromatography–tandem mass spectrometry–based metabolomic screen, we identified the gut microbe–derived metabolite trimethylamine N -oxide (TMAO), which enhanced antitumor immunity to PDAC. Delivery of TMAO intraperitoneally or via a dietary choline supplement to orthotopic PDAC-bearing mice reduced tumor growth, associated with an immunostimulatory tumor-associated macrophage (TAM) phenotype, and activated effector T cell response in the tumor microenvironment. Mechanistically, TMAO potentiated the type I interferon (IFN) pathway and conferred antitumor effects in a type I IFN–dependent manner. Delivering TMAO-primed macrophages intravenously produced similar antitumor effects. Combining TMAO with ICB (anti-PD1 and/or anti-Tim3) in a mouse model of PDAC significantly reduced tumor burden and improved survival beyond TMAO or ICB alone. Last, the levels of bacteria containing CutC (an enzyme that generates trimethylamine, the TMAO precursor) correlated with long-term survival in patients with PDAC and improved response to anti-PD1 in patients with melanoma. Together, our study identifies the gut microbial metabolite TMAO as a driver of antitumor immunity and lays the groundwork for potential therapeutic strategies targeting TMAO.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Moreover, in several cohorts of patients with melanoma, the clinical response to anti-PD-1 antibodies correlated with the expression of the CUTC gene170 in the faecal microbiome40,91,128.”
From Gut OncoMicrobiome Signatures (GOMS) as next-generation biomarkers for cancer immunotherapy (2023) · cites this paper as [170]
In the citing paper
“However, this effect appears to be context-dependent, as preclinical studies in breast159 and pancreatic cancer models160 indicate that TMAO may improve responses to ICIs (Fig. 3a).”
From Gut dysbiosis in oncology: a risk factor for immunoresistance (2026) · doi:10.1038/s41422-025-01212-6 · cites this paper as [160]
In the citing paper
“For instance, TMAO and its microbial precursors reprogrammed tumor-associated macrophages toward a pro-inflammatory, type I interferon (IFN)-dependent phenotype, augmenting CD8+ T-cell activity and potentiating anti-PD-1 efficacy in murine pancreatic cancer.160”
From Gut dysbiosis in oncology: a risk factor for immunoresistance (2026) · doi:10.1038/s41422-025-01212-6 · cites this paper as [160]
In the citing paper
“In an orthotopic PDAC mouse model, TMAO rendered tumours responsive to anti-PD-1 and anti-TIM3 antibodies170.”
From Gut OncoMicrobiome Signatures (GOMS) as next-generation biomarkers for cancer immunotherapy (2023) · cites this paper as [170]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106 · cited 2×
“M. I. Love, W. Huber, S. Anders, Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2.”
Gapped BLAST and PSI-BLAST: a new generation of protein database search programs
Altschul, S. (1997) · Nucleic Acids Research · doi:10.1093/nar/25.17.3389 · Cited by 73,302 · cited 2×
“Reads were aligned against a collection of CutC reference protein sequences that was downloaded through NCBI Reference Sequence Database bacterial (RefSeq), using BlastX (60) with E value < 1 × 10−7.”
MethodFast gapped-read alignment with Bowtie 2
Langmead, B., & Salzberg, S. L. (2012) · Nature Methods · doi:10.1038/nmeth.1923 · Cited by 56,400 · cited 1×
“RNA-seq data were aligned using the bowtie2 (49) algorithm against hg19 human or mm10 mouse genome version, and the RSEM v1.”
MethodCytoscape: A software Environment for integrated models of biomolecular interaction networks
Shannon, P., Markiel, A., Ozier, O., Baliga, N. S., Wang, J. T., Ramage, D., Amin, N., Schwikowski, B., & Ideker, T. (2003) · Genome Research · doi:10.1101/gr.1239303 · Cited by 51,888
STAR: ultrafast universal RNA-seq aligner
Dobin, A., Davis, C. A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., & Gingeras, T. R. (2013) · Bioinformatics · doi:10.1093/bioinformatics/bts635 · Cited by 51,709
Reproducible, interactive, scalable and extensible microbiome data science using QIIME 2
Bolyen, E., Rideout, J. R., Dillon, M. R., Bokulich, N. A., Abnet, C. C., Al-Ghalith, G. A., Alexander, H., Alm, E. J., Arumugam, M., Asnicar, F., et al. (2019) · Nature Biotechnology · doi:10.1038/s41587-019-0209-9 · Cited by 23,742
RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome
Li, B., & Dewey, C. N. (2011) · BMC Bioinformatics · doi:10.1186/1471-2105-12-323 · Cited by 22,179 · cited 1×
“12 software (50) was used to estimate read counts and RPKM (reads per kilobase, per million mapped reads) values using gene information from human Ensembl transcriptome version GRCh37.”
MethodIntegrated analysis of multimodal single-cell data
Hao, Y., Hao, S., Andersen-Nissen, E., Mauck, W. M., Zheng, S., Butler, A., Lee, M. J., Wilk, A. J., Darby, C., Zagar, M., et al. (2020) · doi:10.1101/2020.10.12.335331 · Cited by 15,508 · cited 1×
“Cell clustering, marker identification, and visualization were performed using Seurat v4 (55).”
MethodThe Perseus computational platform for comprehensive analysis of (prote)omics data
Tyanova, S., Temu, T., Sinitcyn, P., Carlson, A., Hein, M. Y., Geiger, T., Mann, M., & Cox, J. (2016) · Nature Methods · doi:10.1038/nmeth.3901 · Cited by 8,803
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Cited by
Items 301–341 of 341
Sikdar, S., Kim, D., Wang, T., Benaoudia, S., Rajwani, J., Ellestad, K. K., Douglas, P., Filandrová, R., Verhey, T. B., Ellestad, K. I., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.04.23.720410
Chen, Z., Jin, D., Wang, H., Bai, Q., Wang, Y., & Gou, Y. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-026-08231-w
“Microbial-derived metabolites can also reduce immunosuppressive cell polarisation and activate effector T cell responses within the TME [19].”
Metabolomics and proteomics in microbiome-cancer analysis
Bilal, A., Ghani, S., Hasan, A., Husain, H., & Husain, A. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-40551-8.00014-7
Mao, X., Cao, Y., Li, J., Niu, T., Li, L., Deng, X., Liu, A., Tang, L., Shi, L., Ji, M., et al. (2026) · Current Proteomics · doi:10.1016/j.curpro.2026.100108
He, J., Bao, J., Deng, S., Zang, W., Yan, H., Zhao, Z., Zhang, G., Liu, R., Chen, J.-X., Hu, Y., et al. (2026) · Advanced Science · doi:10.1002/advs.202521445
Current therapeutic interventions for immune dysregulation induced by gut microbiota
Khatami, F., Karimian, S., & Mohammadipanah, F. (2026) · European journal of medical research · doi:10.1186/s40001-026-04579-3
“Later, several studies further implicated the instrumental function of microbial communities in cancer progression and treatment [62– 65].”
Wang, Y., & Wu, J. (2026) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2026.1860523
Getsina, M. L., Tsyba, N., & Chernevskaya, E. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27135867
“…antitumor immunity in PDAC: experimental data in mouse models show that both intraperitoneal administration of TMAO and dietary choline supplementation reduce tumor growth—this effect is mediated by stimulation of tumor-associated macrophages and activation of effector T-cell responses [70].”
Xie, M.-M., Wang, Y.-L., Liu, J.-X., Li, X., LIU, F., Zheng, W.-R., Xing, W.-Y., Liu, B.-Q., Wu, L., Han, Y., et al. (2026) · European Journal of Nutrition · doi:10.1007/s00394-026-04058-9
Lan, T., Huang, Y., Geng, R., Cen, M., Kang, Q., Kuang, Z., Wang, X., Liu, Z., Chen, J., Zou, C., et al. (2026) · Genes & Diseases · doi:10.1016/j.gendis.2026.102358
Gouveia, L., Serpa, J., & Mendes, C. (2026) · Advances in experimental medicine and biology · doi:10.1007/978-3-032-12166-0_3
Microbiome—pancreatic cancer crosstalk: From tumor biology to therapeutic intervention
薛玉芹, Ye, J., Wang, S., Liu, M., Dai, F., Bai, M., Wang, Y., Savoji, A., Wang, Y., Hylemon, P. B., et al. (2026) · iMetaOmics. · doi:10.1002/imo2.70126
“Dietary strategies complement other microbiota ‐ targeted therapies by shaping the gut ‐ pancreatic microbiome axis to enhance treatment efficacy [328 – 330].”
Lee, J. B., Yang, J., Chalita, M., Jung, Y., Park, H., Ro, M., Kim, H., Yang, E., Choi, S., Kim, M., et al. (2026) · Genome Medicine · doi:10.1186/s13073-026-01736-5
Trimethylamine-N-oxide as a marker of a human metabolism
Belykh, N. А., Lebedeva, I. N., & Маревичева, А. М. (2026) · Russian Journal of Preventive Medicine · doi:10.17116/profmed202629071119
CAFs shape the immunosuppressive microenvironment of pancreatic cancer through the Lin28b-STING Axis
Fan, M., Zhang, Z., Xu, W., Liu, Y., Wang, R., Hao, W., Huo, S., Guo, Y., Wang, L., Lv, A., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-76495-3 · Cited by 1
“In pancreatic cancers, the type I IFN axis has been identi fi ed as a central mediator of anti-tumor immunity 29,44 .”
Liang, F., Li, J., Yue, Y., Pan, J., Liu, C., Cheng, D., Zhang, N., Li, K., Chu, F., & Wu, H. (2026) · Polish Journal of Microbiology · doi:10.33073/pjm-2026-016
“In models of pancreatic ductal adenocarcinoma and triple-negative breast cancer, TMAO potentiated ICI response by activating the dendritic cell– CD8⁺ T-cell axis and M1 macrophages (Mirji et al. 2022; Wang H et al. 2022).”
Zhang, W., Song, L., Sandai, D. A., & Lin, Z. (2026) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2026.2713153
Alotaibi, B. S. (2026) · Saudi Pharmaceutical Journal · doi:10.1007/s44446-026-00107-w
“Tri-methylamine N-oxide was found to induce immune activation and improve the effectiveness of immune checkpoint blockade in pancreatic cancer mouse models (Mirji et al. 2022).”
Protocol for multimodal programming of murine macrophage phenotypes
Mirji, G., Bhat, S. A., & Shinde, R. S. (2026) · STAR Protocols · doi:10.1016/j.xpro.2026.104767
Self-citationJin, H., Sun, H., & Yang, J. (2026) · Molecular Biology Reports · doi:10.1007/s11033-026-12639-4
“TMAO has been associated with enhanced immune checkpoint inhibitor (ICI) responsiveness via activation of type I interferon signaling and reprogramming of macrophage phenotypes [105].”
Bacteriophages as emerging modulators of antitumor immunity in the tumor microenvironment
Chen, X., Zhang, J., Gao, F., & Du, H. (2026) · Microbiological Research · doi:10.1016/j.micres.2026.128700
Panda, P., Mohanty, S., & Mohapatra, R. (2026) · Clinical Microbiology Newsletter · doi:10.1016/j.clinmicnews.2026.08.003
Interplay of gut microbiota, immune cells and natural products in reshaping cancer immunotherapy
Wu, X., Lu, L., Li, T., Zhao, L., Wang, L., Yao, Y., Chen, J., Liu, T., Li, X., Zhu, X., et al. (2026) · Frontiers in Microbiology · doi:10.3389/fmicb.2026.1898063
The hidden microbiome within: microbial architecture of the pancreatic cancer microenvironment
Chohan, S., Punhani, P., Zaheer, S., & Kishore, A. (2026) · Surgical and Experimental Pathology · doi:10.1186/s42047-026-00259-y
Narasimhamurthy, R. K., N, R. K., Rajendra, V. K., & Shetty, P. (2026) · Translational research · doi:10.1016/j.trsl.2026.09.007
Mechanism and clinical relevance of metabolic-immune cross-talk in pancreatic tumor microenvironment
Malik, J. A., Jatavath, M., Fishel, M. L., Bhatia, R., & Gautam, S. K. (2026) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2026.08.005
Decoding the cancer microbiome: multi-omics, AI, and translational opportunities
Sun, Y., Cheng, O., Ma, A., Shabnaz, S., Huang, X., Zhao, J., Tan, A. C., & Ma, Q. (2026) · Genome biology · doi:10.1186/s13059-026-04284-8
“At the species and metabolite level, studies across different tumor models have shown that taxa such as Akkermansia muciniphila , Enterococcus hirae , and Faecalibacterium prausnitzii , as well as metabolites including short-chain fatty acids and TMAO, can modulate antitumor immunity [256–260].”
Nanoparticle pharmacomicrobiomics: Reprogramming the microbiome–immune axis for cancer immunotherapy
Siddiqua, K. S., Farooqui, S. A., Zhang, Y., Wang, L., Zhang, G., Jiang, F., & 文庭池 (2026) · Pharmacological Research · doi:10.1016/j.phrs.2026.108481
Gao, W., Wang, X., Shi, Y., Wu, G., Zhou, M., & Lin, X. (2026) · Genes and Immunity · doi:10.1038/s41435-026-00413-2
“One study has shown that a microbe-derived metabolite, trimethylamine oxide, can drive the activation of anti-tumor immunity, enhancing the therapeutic response of pancreatic cancer to immune checkpoint blocking therapy [11].”
The Gut–Prostate Axis: Mechanistic Insights and Nanotechnology Driven Therapeutic Strategies
Mansour, R. M., Salah, A. N., Mageed, S. S. A., El-Sayyad, G. S., Rizk, N. I., Gaballah, M. S. A., zakaria, G., Abdelaziz, M. M., Fahmy, H. A., Shaker, A. A. S., et al. (2026) · Comprehensive physiology · doi:10.1002/cph4.70274
Research progress in intratumoral microbiota: unlocking the potential of cancer immunotherapy
Tian, T., & Chen, M. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1956198
Yang, J., Cai, X., He, F., 张君红, Zhang, Z., Yi, Z., Xie, C., & Xu, B. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02903-1
Rajabi, E., Seyedi, Z. P., Ghamari, M., Mohammadzadeh, R., Mansouri, M., Götz, F., & Bostanghadiri, N. (2026) · Infectious Medicine · doi:10.1016/j.imj.2026.100290
Zhong, D., Li, C., & Xiao, Z. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1938564
Mimpen, I. L., Toner-Bartelds, C., Parra-Martinez, M., Riccò, B., Catsman, J. J. I., Stigter, E. C. A., van Faassen, M. H. J. R., Björk, J. R., Burgering, B. M. T., Dijkstra, K. K., et al. (2026) · Scientific Reports · doi:10.1038/s41598-026-76464-2
Turabi, K. S., Sardarni, U. K., Ankenbauer, K. E., Torbit, S. M., Taranto, C. P., Dash, S., Meade, A., Cephas, A., Klute, K. A., di Magliano, M. P., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.10.20.760559
Wei, Z. (2026) · The Innovation Nutrition · doi:10.59717/j.xinn-nutri.2026.100043
Antibiotics and outcomes of cancer immunotherapy: An updated meta-analysis and clinical applications
Porcari, S., Bolte, L. A., Björk, J. R., Elkrief, A., Derosa, L., Ferrari, M., Pezzullo, A. M., Severino, A., Fusco, W. G., Messaoudene, M., et al. (2026) · Cancer Cell · doi:10.1016/j.ccell.2026.09.012
Shen, B., Luo, Y., Tang, X., Hu, Z., He, Q., & Wang, L. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.2004691
Cheng, S., Zhang, Y., Li, W., Xu, G., & Qu, J. (2026) · Biomedicines · doi:10.3390/biomedicines14112485
Xu, H., Kong, H.-X., Lin, Y., Zhou, Y.-J., Liang, W.-L., & Huang, H.-L. (2026) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.126454
Metadata
- Authors
- Mirji, G., Worth, A., Bhat, S. A., El Sayed, M., Kannan, T., Goldman, A. R., Tang, H.-Y., Liu, Q., Auslander, N., Dang, C. V., Abdel-Mohsen, M., Kossenkov, A., Stanger, B. Z., & Shinde, R. S.
- Affiliations
- The Wistar Institute (US)
- Immunology, Microenvironment and Metastasis Program, the Wistar Institute, Philadelphia, PA, USA.
- University of Pennsylvania (US)
- Corresponding author
- Shinde, Rahul S.
- ORCID
- Venue
- Science Immunology
- Published
- 2022-09-30
- Volume
- 7
- Issue
- 75
- Pages
- eabn0704-eabn0704
- ISSN
- 2470-9468 (ISSN-L)
- PMC
- PMC9925043
- OpenAlex
- W4295519447
- Cited by
- 327
- References
- 62
- Citations by year
- 2026: 83 · 2025: 91 · 2024: 89 · 2023: 62 · 2022: 2
- FWCI
- 26.30
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science Immunology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (1s10od023586-01)
- National Cancer Institute (R01CA057341, R21CA259240, R50CA221838, R50CA211199, R01CA252225, P30CA010815)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Keywords
- trimethylamine N-oxide, gut microbiota, pancreatic ductal adenocarcinoma, immune checkpoint blockade, antitumor immunity, tumor-associated macrophages, type I interferon pathway, choline, CutC, anti-PD-1, effector T cells, tumor microenvironment, melanoma
- MeSH terms
- Gastrointestinal Microbiome, Immune Checkpoint Inhibitors, Animals, Methylamines, Pancreatic Neoplasms, Mice, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.